William Blair Remains a Buy on Baldwin Insurance Group (BWIN)
William Blair analyst Adam Klauber maintained a Buy rating on Baldwin Insurance Group (BWIN – Research Report) today. The company’s shares ...
Nektar Therapeutics’ (NKTR) “Market Perform” Rating Reaffirmed at William Blair
William Blair reiterated their market perform rating on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a report issued on Tuesday,RTT News reports. Other research analysts have also ...
William Blair Reaffirms Their Buy Rating on Novanta (NOVT)
In a report released today, Brian Drab from William Blair maintained a Buy rating on Novanta (NOVT – Research Report). The company’s shares ...
BioSpace6d
5 Pharma Powerhouses Facing Massive Patent Cliffs—And What They’re Doing About It
Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...
Hosted on MSN4d
William Blair Downgrades CACI International (CACI)
Fintel reports that on February 21, 2025, William Blair downgraded their outlook for CACI International (NYSE:CACI) from ...
William Blair Issues Negative Outlook for AMN Earnings
Stock analysts at William Blair lowered their Q1 2025 EPS estimates for shares of AMN Healthcare Services in a report issued ...
Hosted on MSN4d
William Blair Downgrades Parsons (PSN)
Fintel reports that on February 21, 2025, William Blair downgraded their outlook for Parsons (NYSE:PSN) from Outperform to Market Perform. Analyst Price Forecast Suggests 97.12% Upside As of February ...
BioSpace2d
Vertex’s Journavx Changes the Pain Treatment Landscape But Opioids Here to Stay
Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...
Insulet's Strong Q4 Highlights Surging Omnipod Demand And Growth Potential: Analyst
Insulet Corporation (NASDAQ:PODD) reported fourth-quarter adjusted EPS of $1.15, down from $1.40 a year ago but beating the ...
Nasdaq5d
William Blair Downgrades General Dynamics (WBAG:GEDY)
Fintel reports that on February 21, 2025, William Blair downgraded their outlook for General Dynamics (WBAG:GEDY) from Outperform to Market Perform. There are 2,727 funds or institutions reporting ...